Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease.

Although 30 mg/kg deferiprone treated patients showed a trend for improvement in motor-UPDRS scores and quality of life, this did not reach significance.

also in 53,322 other papers

A similar but more pronounced trend was observed with the PDQ-39 scores, with the placebo and 20 mg/kg/day PD groups showing strong trends for worsening quality of life whilst the 30 mg/kg/day deferiprone PD group showed a slight improvement over 6 months but this did not reach statistical significance (Fig. 2B ).

also in 111,027 other papers